{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:51:24Z","timestamp":1778881884240,"version":"3.51.4"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T00:00:00Z","timestamp":1567036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Advanced-stage Hodgkin lymphoma (HL) is a curable malignancy, although outcomes remain poor in certain patients. It remains unclear if recent advances have improved their population-level survival over time.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>Using the Surveillance, Epidemiology, and End Results database, we identified patients aged \u226518\u2009years with stage III or IV classical HL as the first primary malignancy, diagnosed between 2000 and 2014 and treated with chemotherapy. Patients were stratified by date of diagnosis into three groups (2000\u20132004, 2005\u20132009, 2010\u20132014) to assess the trends in overall survival (OS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 9,042 patients with a median age of 41\u2009years were included. The use of frontline radiation therapy decreased in each period (21.3% [2000\u20132004] vs. 15.5% [2005\u20132009] vs. 10.7% [2010\u20132014]; p &amp;lt; .001). Three-year OS was significantly higher for patients diagnosed between 2010 and 2014 (81.8%) and 2005 and 2009 (80.6%) compared with 2000 and 2004 (78.5%; p = .0008 and .02, respectively). Whereas outcomes were poorest in the age &amp;gt;60 cohort, similar improvements were also seen in 3-year OS over the three time periods within this patient population. On multivariate analysis, diagnosis in the earlier period and minority race were associated with higher mortality. Females and married patients had significantly lower mortality risk.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Survival of patients with advanced-stage HL has continued to improve over time, suggesting the impact of evolving treatment approaches. Three-year OS in the contemporary period remains inadequate at 81.8%, highlighting the need for continued research to improve their outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>This article evaluates contemporary outcomes for advanced-stage Hodgkin lymphoma (HL) in the U.S. using the Surveillance, Epidemiology, and End Results database. Although overall survival (OS) has improved in each 5-year period since 2000, the 3-year OS from 2010 to 2014 remains inadequate at 81.8% and is limited by patient demographics. New therapies are indicated to improve clinical outcomes in advanced-stage HL.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0172","type":"journal-article","created":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T19:14:15Z","timestamp":1567106055000},"page":"1488-1495","source":"Crossref","is-referenced-by-count":11,"title":["Contemporary Outcomes for Advanced-Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and End Results Database"],"prefix":"10.1093","volume":"24","author":[{"given":"Guru Subramanian","family":"Guru Murthy","sequence":"first","affiliation":[{"name":"Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aniko","family":"Szabo","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[{"name":"Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA"},{"name":"CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy S.","family":"Fenske","sequence":"additional","affiliation":[{"name":"Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirav N.","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,8,29]]},"reference":[{"key":"2021122508044941400_onco13081-bib-0001","year":"2018"},{"key":"2021122508044941400_onco13081-bib-0002","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1200\/JCO.2013.53.1194","article-title":"Treatment of Hodgkin lymphoma: A 50-year perspective","volume":"32","author":"Canellos","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122508044941400_onco13081-bib-0003","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"key":"2021122508044941400_onco13081-bib-0004","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/cam4.655","article-title":"Improved survival time trends in Hodgkin's lymphoma","volume":"5","author":"Koshy","year":"2016","journal-title":"Cancer Med"},{"key":"2021122508044941400_onco13081-bib-0005","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/bjc.2012.228","article-title":"Long-term survival after treatment for Hodgkin's disease (1973-2002): Improved survival with successive 10-year cohorts","volume":"107","author":"Bessell","year":"2012","journal-title":"Br J Cancer"},{"key":"2021122508044941400_onco13081-bib-0006","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122508044941400_onco13081-bib-0007","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122508044941400_onco13081-bib-0008","author":"Surveillance, Epidemiology, and End Results (SEER) Program"},{"key":"2021122508044941400_onco13081-bib-0009","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"2021122508044941400_onco13081-bib-0010","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned","volume":"365","author":"Viviani","year":"2011","journal-title":"N Engl J Med"},{"key":"2021122508044941400_onco13081-bib-0011","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S1470-2045(17)30103-1","article-title":"Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP escalated alone or in combination with rituximab (HD18): An open-label, international, randomised phase 3 study by the German Hodgkin Study Group","volume":"18","author":"Borchmann","year":"2017","journal-title":"Lancet Oncol"},{"key":"2021122508044941400_onco13081-bib-0012","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/bjh.14379","article-title":"Survival differences between patients with Hodgkin lymphoma treated inside and outside clinical trials. A study based on the EORTC-Netherlands Cancer Registry linked data with 20\u2009years of follow-up","volume":"176","author":"Liu","year":"2017","journal-title":"Br J Haematol"},{"key":"2021122508044941400_onco13081-bib-0013","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2011.41.0910","article-title":"International Prognostic Score in advanced-stage Hodgkin's lymphoma: Altered utility in the modern era","volume":"30","author":"Moccia","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122508044941400_onco13081-bib-0014","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"key":"2021122508044941400_onco13081-bib-0015","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/bjh.12722","article-title":"Improved population level survival in younger Hodgkin lymphoma patients in Germany in the early 21st century","volume":"164","author":"Pulte","year":"2014","journal-title":"Br J Haematol"},{"key":"2021122508044941400_onco13081-bib-0016","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1093\/annonc\/mdv359","article-title":"Era-by-era improvement in survival for elderly patients with Hodgkin lymphoma; outcome data from a large population-based cohort","volume":"26","author":"Bishton","year":"2015","journal-title":"Ann Oncol"},{"key":"2021122508044941400_onco13081-bib-0017","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1634\/theoncologist.2008-0285","article-title":"Survival expectations of patients diagnosed with Hodgkin's lymphoma in 2006-2010","volume":"14","author":"Brenner","year":"2009","journal-title":"The Oncologist"},{"key":"2021122508044941400_onco13081-bib-0018","doi-asserted-by":"crossref","first-page":"725219","DOI":"10.1155\/2011\/725219","article-title":"Incidence patterns and outcomes for Hodgkin lymphoma patients in the United States","volume":"2011","author":"Shenoy","year":"2011","journal-title":"Adv Hematol"},{"key":"2021122508044941400_onco13081-bib-0019","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1634\/theoncologist.2017-0541","article-title":"Long-term survival rates of patients with stage III-IV Hodgkin lymphoma according to age, sex, race, and socioeconomic status, 1984-2013","volume":"23","author":"Li","year":"2018","journal-title":"The Oncologist"},{"key":"2021122508044941400_onco13081-bib-0020","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/cncr.30979","article-title":"Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis","volume":"124","author":"Henderson TO","year":"2018","journal-title":"Cancer"},{"key":"2021122508044941400_onco13081-bib-0021","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma","volume":"36","author":"Evens","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021122508044941400_onco13081-bib-0022","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.clml.2017.02.003","article-title":"Systemic anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: A population-based analysis of incidence and survival","volume":"17","author":"Guru Murthy","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2021122508044941400_onco13081-bib-0023","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/annonc\/mdr578","article-title":"Racial disparities in Hodgkin's lymphoma: A comprehensive population-based analysis","volume":"23","author":"Evens","year":"2012","journal-title":"Ann Oncol"},{"key":"2021122508044941400_onco13081-bib-0024","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3322\/caac.21340","article-title":"Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities","volume":"66","author":"DeSantis","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"2021122508044941400_onco13081-bib-0025","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ijc.31096","article-title":"Lower socioeconomic status is independently associated with shorter survival in Hodgkin Lymphoma patients-An analysis from the Brazilian Hodgkin Lymphoma Registry","volume":"142","author":"Biasoli","year":"2018","journal-title":"Int J Cancer"},{"key":"2021122508044941400_onco13081-bib-0026","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"2021122508044941400_onco13081-bib-0027","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: A multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"2021122508044941400_onco13081-bib-0028","doi-asserted-by":"crossref","first-page":"903","DOI":"10.7326\/0003-4819-120-11-199406010-00002","article-title":"Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study","volume":"120","author":"Fabian","year":"1994","journal-title":"Ann Intern Med"},{"key":"2021122508044941400_onco13081-bib-0029","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa022628","article-title":"Involved-field radiotherapy for advanced Hodgkin's lymphoma","volume":"348","author":"Aleman","year":"2003","journal-title":"N Engl J Med"},{"key":"2021122508044941400_onco13081-bib-0030","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S1470-2045(16)30215-7","article-title":"Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin's lymphoma: An analysis from the St Jude Lifetime Cohort Study","volume":"17","author":"Bhakta","year":"2016","journal-title":"Lancet Oncol"},{"key":"2021122508044941400_onco13081-bib-0031","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40\u2009years after treatment for Hodgkin's lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122508044941400_onco13081-bib-0032","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2002-02-0634","article-title":"Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: Long-term risks and risk factors","volume":"100","author":"Ng","year":"2002","journal-title":"Blood"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0172","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0172","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/11\/1488\/41918053\/oncolo_24_11_1488.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/11\/1488\/41918053\/oncolo_24_11_1488.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T08:06:25Z","timestamp":1640419585000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/11\/1488\/6439841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,29]]},"references-count":32,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,8,29]]},"published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0172","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11,1]]},"published":{"date-parts":[[2019,8,29]]}}}